Although mTOR pathway inhibition is a current targeted therapy strategy, several in vitro and in vivo studies have shown that DDIT4 expression could lead to cancer progression, resistance to treatment and angiogenesis, raising an important question about the mTOR biology. Here, DDIT4 is linked to cancer.